AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- Nabi Biopharmaceuticals (NABI) has continued to advance the development of StaphVAX (Staphylococcus aureus polysaccharide conjugate vaccine) and announced updates to its manufacturing and clinical trial plans.
Currently in a confirmatory phase III clinical trial, StaphVAX is the company's investigational vaccine that is designed to prevent Staphylococcus aureus blood stream infections.
Nabi Biopharmaceuticals continues to make progress towards the manufacture of StaphVAX consistency lots at Cambrex Bio Science, Inc., to support the license application with the European Union planned for the end of 2004.
Capacity at Cambrex can support the launch of StaphVAX in Europe and the initial launch in the U.S. Recognizing that the peak forecasted demand is expected to be substantially ...